Table 5.
Univariate analysis of the correlation of clinicopathological parameters with overall survival in CRC celecoxib subgroup
| HR | 95%CI | P value | |
| Sex, male vs female | 0.854 | 0.329-2.219 | 0.74 |
| Age in yr, ≤ 60 vs > 60 | 1.249 | 0.432-3.609 | 0.70 |
| Cancer, colon vs rectum | 1.034 | 0.420-2.543 | 0.94 |
| BMI, > 25 vs ≤ 25 | 1.328 | 0.351-5.020 | 0.71 |
| Tumor differentiation, moderate and poor vs well | 7.396 | 2.749-19.90 | 0.021 |
| Stage, 3 vs 2 | 1.075 | 0.415-2.782 | 0.88 |
| T stage, T4 vs T2/3 | 1.389 | 0.537-3.596 | 0.50 |
| N stage, N1/2 vs N0 | 1.075 | 0.415-2.782 | 0.88 |
| CEA in ng/mL, > 5 vs ≤ 5 | 1.934 | 0.743-5.033 | 0.21 |
| CA19-9 in m/L, > 37 vs ≤ 37 | 1.551 | 0.431-5.575 | 0.43 |
| CD3 TILs, high vs low | 1.02 | 0.414-2.510 | 0.97 |
| CD8 TILs, high vs low | 2.821 | 0.774-10.29 | 0.026 |
| Nuclear IDO1, high vs low | 3.023 | 0.585-15.61 | 0.041 |
| Cytoplasmic IDO1, high vs low | 1.623 | 0.617-4.267 | 0.31 |
| Nuclear and cytoplasmic IDO1, high vs low | 3.023 | 0.585-15.61 | 0.041 |
| COX2, high vs low | 1.746 | 0.672-4.541 | 0.25 |
| Nuclear IDO1/COX2, IV vs I/II/III | 1.885 | 0.279-12.76 | 0.38 |
| Cytoplasmic IDO1/COX2, IV vs I/II/III | 2.740 | 0.764-9.831 | 0.038 |
BMI: Body mass index; CA: Cancer antigen; CEA: Carcinoembryonic antigen; CI: Confidence interval; COX2: Cyclooxygenase 2; CRC: Colorectal carcinoma; HR: Hazard ratio; IDO1: Indoleamine-2,3-dioxygenase 1; TILs: Tumor infiltrating lymphocytes.